Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,248 GBp
Change Today +130.50 / 3.17%
Volume 3.3M
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 11:35 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ASTRAZENECA PLC (AZN) in the last 6 months

Announced 09/2/15
80.00M for ADC Therapeutics Sarl
Private Placement

ADC Therapeutics Sarl announced that it has received $80 million in an equity round of funding on September 2, 2015. The transaction included participation from new European and US-based investors and existing investors, Auven Therapeutics Management L.L.L.P and AstraZeneca PLC.


AZN's price was unchanged after the transaction was announced on 09/2/15.
Investor / Buyer
AstraZeneca PLC
Auven Therapeutics Management L.L.L.P
 
Announced 08/6/15
510.00M for Heptares Therapeutics Ltd., Global Rights of HTL-1071
Merger/Acquisition

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Global rights of HTL-1071 from Heptares Therapeutics Ltd. for $510 million on August 6, 2015. Under the terms of an agreeement, Heptares will receive an upfront payment of $10 million and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events up to the maximum of $500 million, as well as up to double-digit tiered royalties on net sales. ...
Read More


AZN's price was unchanged after the transaction was announced on 08/6/15.
Investor / Buyer
AstraZeneca PLC
Creditor / Lender
Heptares Therapeutics Ltd.
 
Announced 07/27/15
300.00M for AstraZeneca PLC, Caprelsa
Merger/Acquisition

Genzyme Corporation entered into a definitive agreement to acquire Caprelsa from AstraZeneca PLC (LSE:AZN) for $300 million on July 27, 2015. The deal value includes an upfront payment of $165 million and further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities. Caprelsa reported global product sales of $48 million in 2014. The transaction is subject to closing conditions, ...
Read More


AZN's price was unchanged after the transaction was announced on 07/27/15.
Investor / Buyer
Genzyme Corporation
Creditor / Lender
AstraZeneca PLC
 
Announced 03/31/15
40.00M for Entasis Therapeutics
Private Placement

Entasis Therapeutics announced that it has received $40 million in its series A round of funding from AstraZeneca PLC in March 2015.


AZN's price was unchanged after the transaction was announced on 03/31/15.
Investor / Buyer
AstraZeneca PLC
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,247.50 GBp +130.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $141.74 USD +0.50
BASF SE €70.77 EUR +0.01
Biogen Inc $301.63 USD -2.58
Eli Lilly & Co $81.60 USD -0.21
Valeant Pharmaceuticals International Inc C$301.25 CAD -6.75
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 67.5x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 67.5x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.